Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 525 of 1475 entries
View as:

MAD Refractory: Solid Tumor QD w/o Break

Phase: N/A Priority: Normal
NCT ID: NCT00207012 Org: User:
Start: 05/31/04 End: - Due: -

Safety Study of BMS-823778 in Subjects With Hypercholesterolemia

Phase: N/A Priority: Normal
NCT ID: NCT01112423 Org: User:
Start: 06/30/10 End: 12/31/10 Due: 12/31/11

Clinical Trial Comparing Safety and Pharmacokinetics of Standard Antibiotic Therapy, Plus Aurexis® or Placebo, for Treatment of Staphylococcus Aureus Bacteremia (SAB)

Phase: N/A Priority: Normal
NCT ID: NCT00198302 Org: User:
Start: - End: 02/28/05 Due: 02/28/06

Study to Assess the Effect of Branebrutinib on the Drug Levels of Rosuvastatin in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT04515628 Org: User:
Start: 08/02/20 End: 10/26/20 Due: 10/26/21

A Multicenter, Double Blind, Placebo-Controlled, Safety and Tolerability Study of BMS-708163 in Patients With Prodromal Alzheimer's Disease

Phase: N/A Priority: Normal
NCT ID: NCT00890890 Org: User:
Start: 05/31/09 End: 07/31/13 Due: 07/31/14

A Study of the Comparative Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in Japan (RePhlect)

Phase: N/A Priority: Normal
NCT ID: NCT06382987 Org: User:
Start: 01/22/24 End: 12/31/29 Due: 12/31/30

Induction-Maintenance With Atazanavir in HIV Naïve Patients (The INDUMA Study)

Phase: N/A Priority: Normal
NCT ID: NCT00207142 Org: User:
Start: 11/30/05 End: 01/31/08 Due: 01/31/09

A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers

Phase: N/A Priority: Normal
NCT ID: NCT03400332 Org: User:
Start: 02/12/18 End: 11/30/25 Due: 11/30/26

A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)

Phase: N/A Priority: Normal
NCT ID: NCT02588625 Org: User:
Start: 02/29/16 End: 10/31/19 Due: 10/31/20

Comparability DE vs CD-CHO1

Phase: N/A Priority: Normal
NCT ID: NCT00277199 Org: User:
Start: 09/30/02 End: 12/31/02 Due: 12/31/03

A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)

Phase: N/A Priority: Normal
NCT ID: NCT07011745 Org: User:
Start: 07/18/25 End: 11/08/28 Due: 11/08/29

A Study to Determine the Risk of Cancer in Rheumatoid Arthritis (RA) Patients Who Use Abatacept and Other Biologic Agents

Phase: N/A Priority: Normal
NCT ID: NCT03670667 Org: User:
Start: 02/22/17 End: 03/29/19 Due: 03/29/20

BMS-986325 in Healthy Participants and Participants With Primary Sjögren's Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT04684654 Org: User:
Start: 02/16/21 End: 07/25/23 Due: 07/25/24

Comparison Study of MDX-010 (CTLA-4) Alone and Combined With DTIC in the Treatment of Metastatic Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT00050102 Org: User:
Start: 10/31/02 End: 02/29/04 Due: 02/28/05

Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone

Phase: N/A Priority: Normal
NCT ID: NCT01605084 Org: User:
Start: 06/30/12 End: 08/31/14 Due: 08/31/15

An Investigational Study to Evaluate Experimental Medication BMS-986036 in Participants With Different Levels of Kidney Function

Phase: N/A Priority: Normal
NCT ID: NCT03674476 Org: User:
Start: 09/11/18 End: 06/24/19 Due: 06/24/20

Study to Evaluate Effect of Belatacept on Pharmacokinetics of Inje Cocktail in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01766050 Org: User:
Start: 01/31/13 End: 04/30/13 Due: 04/30/14

A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT03141177 Org: User:
Start: 07/23/17 End: 01/16/26 Due: 01/16/27

Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC

Phase: N/A Priority: Normal
NCT ID: NCT00908752 Org: User:
Start: 07/20/09 End: 01/26/18 Due: 01/26/19

Impact of Anti-citrullinated Protein Antibody Status on Treatment Response and Treatment Persistence in Participants With Rheumatoid Arthritis (RA) Who Are Treated With Abatacept or Tumor Necrosis Factor Inhibitors in Australia

Phase: N/A Priority: Normal
NCT ID: NCT03663829 Org: User:
Start: 10/04/17 End: 12/18/19 Due: 12/18/20

Pravastatin or Atorvastatin Evaluation and Infection Therapy (TIMI22)

Phase: N/A Priority: Normal
NCT ID: NCT00382460 Org: User:
Start: 11/30/00 End: 12/31/03 Due: 12/31/04

A Study of BMS-863233 in Patients With Hematologic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00838890 Org: User:
Start: 03/31/09 End: 01/31/10 Due: 01/31/11

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)

Phase: N/A Priority: Normal
NCT ID: NCT01721746 Org: User:
Start: 12/21/12 End: 12/29/20 Due: 12/29/21

Safety Study of BMS-770767 in Subjects With Hypercholesterolemia

Phase: N/A Priority: Normal
NCT ID: NCT01058083 Org: User:
Start: 05/31/10 End: 03/31/11 Due: 03/31/12

A Study to Evaluate Efficacy and Safety of Subcutaneous Abatacept With Steroid Treatment Compared to Steroid Treatment Alone in Adults With Giant Cell Arteritis (GCA)

Phase: N/A Priority: Normal
NCT ID: NCT03192969 Org: User:
Start: 07/15/17 End: 11/23/21 Due: 11/23/22